-
Celularity secures up to $12 million in binding financing agreements
-
Celularity receives FDA warning letter over Interfyl marketing claims
-
Celularity partners with DefEYE for eye care biologics licensing deal
-
WBB Securities Upgrades Celularity (CELU) to Buy
-
WBB Securities Starts Celularity (CELU) at Speculative Buy
-
Celularity retires $41.6 million senior secured debt through IP sale
-
Celularity (CELU) Announces CFO Transition
-
Celularity (CELU) Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
-
Celularity (CELU) Files for 4.63M Share and Warrant Offering
-
Celularity (CELU) Announces Resolution of Nasdaq Listing Compliance Matter
-
Celularity (CELU) Receives Nasdaq Non-compliance Notice
-
Celularity (CELU) Provides Corporate Update
-
Celularity (CELU) Acquires Rebound Product from Sequence LifeScience
-
Celularity (CELU) Appoints Richard J. Berman to its Board

